Merck Sharp & Dohme 8-K Merck Announces Strong Financial Results for the First Quarter 2006

Exhibit 99.2

MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
FIRST QUARTER
2006

OTHER (INCOME)/EXPENSE, NET (millions of dollars)

	1Q `06			1Q `05
INTEREST INCOME	$	(181.7	)	$	(93.8	)
INTEREST EXPENSE		98.2			84.5
EXCHANGE (GAINS)/LOSSES		(0.4	)		(0.7	)
MINORITY INTERESTS		29.9			30.4
Other, net		(46.6	)		6.1
TOTAL	$	(100.6	)	$	26.5

JOINT VENTURE SALES DETAIL (millions of dollars)

All sales reported here are end-market JV sales, presented on a “NET” basis.

Merial	1Q `06		1Q `05
IVOMEC, HEARTGARD, other avermectins	$	129.5	$	116.7
FRONTLINE		261.5		201.8
Biologicals		139.5		120.4
Other Animal Health		55.2		55.7
TOTAL MERIAL SALES	$	585.7	$	494.6

Sanofi Pasteur-MSD	1Q `06		1Q `05
HEPATITIS VACCINES	$	19.1	$	21.9
VIRAL VACCINES		21.7		16.8
Other Vaccines		131.9		131.0
TOTAL SANOFI-MSD SALES	$	172.7	$	169.7

Merck / Schering-Plough Collaboration	1Q `06		1Q `05
VYTORIN (Worldwide)	$	378.4	$	179.0
ZETIA (Worldwide)		414.8		331.6
TOTAL	$	793.2	$	510.6

Exhibit 99.2

MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
FIRST QUARTER
2006

NET PRODUCT SALES DETAIL (millions of dollars)

	1Q `06 vs. 1Q `05
	TOTAL			TOTAL		U.S.			U.S.		Foreign			Foreign
PRODUCT	% CHG			$		% CHG			$		% CHG			$
COZAAR / HYZAAR		-2	%		701		-1	%		231		-3	%		470
FOSAMAX		-2	%		754		11	%		457		-18	%		297
SINGULAIR		9	%		801		17	%		576		-7	%		225
ZOCOR		-4	%		1,063		13	%		833		-37	%		231
Other Reported Products:
AGGRASTAT		-2	%		22		N/A			—		-2	%		22
ARCOXIA		5	%		59		N/A			—		5	%		59
CANCIDAS		12	%		146		16	%		78		8	%		69
COSOPT / TRUSOPT		8	%		152		14	%		57		5	%		95
CRIXIVAN / STOCRIN		4	%		82		-26	%		7		8	%		75
EMEND		30	%		23		9	%		17		*			6
INVANZ		45	%		28		29	%		16		74	%		12
MAXALT		20	%		93		21	%		58		17	%		35
PRIMAXIN		-8	%		170		-7	%		50		-9	%		119
PROPECIA		7	%		75		7	%		34		8	%		41
PROSCAR		7	%		188		21	%		96		-4	%		92
TIMOPTIC / TIMOPTIC XE		-6	%		30		-17	%		2		-5	%		28
VASOTEC / VASERETIC		-14	%		136		N/A			—		-14	%		136
HEPATITIS VACCINES		51	%		54		70	%		41		9	%		12
VIRAL VACCINES		21	%		161		19	%		136		36	%		26
OTHER VACCINES		3	%		56		5	%		41		-3	%		16

*	100% or over
	N/A — Not Applicable

TOTAL SALES: VOLUME, PRICE, EXCHANGE

	1Q '06		% CHG.			VOL		PX		FX
TOTAL PHARMACEUTICAL SALES	$	5,410		1	%		1		2		-2
U.S. ($ MM)		3,247		8	%		2		6		N/A
Foreign ($ MM)		2,163		-8	%		-1		-2		-5